Hormone Insight

FWA
  • 0.0 (0)
  • Education

Discuss Diabetes and Endocrinology studies in a simplified manner. Expand your knowledge in Diabetes and Endocrinology.

  1. 15h ago

    SURMOUNT-1: 20% weight loss | Hormone Insight Podcast

    Does once-weekly tirzepatide reduce body weight in adults with obesity? In adults with obesity, once-weekly tirzepatide reduced body weight substantially more than placebo over 72 weeks, by up to about 21%. Randomized trial · NEJM 2022 Reference: Jastreboff AM, Aronne LJ, Ahmad NN. N Engl J Med. 2022; PMID:35658024 Chapters 0:00 Intro 0:38 The trial 3:12 My take 3:48 Outro Read the structured trial summary at https://hormoneinsight.com/ AI-generated narration. This podcast is intended for healthcare professionals and is for educational purposes only; it is not medical advice. Any views expressed are the presenter's own and do not necessarily reflect the views of any institution he works with. Explore Hormone Insight: Website: https://hormoneinsight.com/ Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856 Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

  2. 1d ago

    POLY-HF: One pill for heart failure? | Hormone Insight Podcast

    Can a polypill improve heart-failure treatment? Combining three heart-failure medicines into one daily capsule improved six-month MRI-measured ejection fraction versus actively optimized separate medicines. Secondary clinical-event findings are encouraging but do not establish a mortality benefit. Randomized trial · Nature Medicine 2026 Reference: Pandey A, Keshvani N, Rizvi SK, et al. Polypill for heart failure with reduced ejection fraction: the POLY-HF randomized trial. Nat Med. 2026;32:2933–2940. doi:10.1038/s41591-026-04504-5. PMID:42393373. Chapters 0:00 Intro 0:38 The trial 3:23 My take 4:01 Outro Read the structured trial summary at hormoneinsight.com This podcast is intended for healthcare professionals only. It is educational and is not medical advice. Any views expressed are the presenter's own and do not necessarily reflect the views of any institution he works with. AI narration disclosure: This episode uses AI-generated narration. For healthcare professionals. Educational content only; not medical advice or a substitute for clinical judgement, individual assessment or current guidance. Hormone Insight: https://hormoneinsight.com/ Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856 Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

  3. 2d ago

    SUMMIT: Tirzepatide in HFpEF | Hormone Insight Podcast

    Does tirzepatide improve cardiovascular outcomes and quality of life in patients with heart failure with preserved ejection fraction and obesity? In patients with heart failure with preserved ejection fraction and obesity, tirzepatide reduced the risk of cardiovascular death or worsening heart failure and improved health status compared with placebo. Randomized trial · NEJM 2025 Reference: Packer M, Zile MR, Kramer CM. N Engl J Med. 2025; PMID: 39555826 Chapters 0:00 Intro 0:38 The trial 3:27 My take 4:02 Outro Read the structured trial summary at hormoneinsight.com This podcast is intended for healthcare professionals only. It is educational and is not medical advice. Any views expressed are the presenter's own and do not necessarily reflect the views of any institution he works with. AI narration disclosure: This episode uses AI-generated narration. For healthcare professionals. Educational content only; not medical advice or a substitute for clinical judgement, individual assessment or current guidance. Hormone Insight: https://hormoneinsight.com/ Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856 Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

  4. 3d ago

    EMPA-KIDNEY: SGLT2 for all CKD | Hormone Insight Podcast

    Does empagliflozin help patients with chronic kidney disease? In patients with chronic kidney disease at risk of progression, empagliflozin reduced the risk of kidney-disease progression or cardiovascular death compared with placebo by about 28%. Randomized trial · NEJM 2023 Reference: The EMPA-KIDNEY Collaborative Group. Empagliflozin in Patients with Chronic Kidney Disease. The New England journal of medicine. 2023;388(2):117-127. doi:10.1056/NEJMoa2204233. PMID:36331190. Chapters 0:00 Intro 0:38 The trial 3:33 My take 4:11 Outro Read the structured trial summary at hormoneinsight.com This podcast is intended for healthcare professionals only. It is educational and is not medical advice. Any views expressed are the presenter's own and do not necessarily reflect the views of any institution he works with. AI narration disclosure: This episode uses AI-generated narration. For healthcare professionals. Educational content only; not medical advice or a substitute for clinical judgement, individual assessment or current guidance. Hormone Insight: https://hormoneinsight.com/ Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856 Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

  5. 4d ago

    FLOW: Semaglutide and the kidney | Hormone Insight Podcast

    Does semaglutide reduce kidney and cardiovascular risks in patients with type 2 diabetes and chronic kidney disease? In patients with type 2 diabetes and chronic kidney disease, once-weekly semaglutide 1.0 mg reduced the risk of major kidney disease events and death from cardiovascular causes compared with placebo (about 24% lower primary-outcome risk). Randomized trial · NEJM 2024 Reference: Perkovic V, Tuttle KR, Rossing P. N Engl J Med. 2024; PMID: 38785209. Chapters 0:00 Intro 0:38 The trial 3:58 My take 4:35 Outro AI narration disclosure: This episode uses AI-generated narration. For healthcare professionals. Educational content only; not medical advice or a substitute for clinical judgement, individual assessment or current guidance. Hormone Insight: https://hormoneinsight.com/ Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856 Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

  6. 5d ago

    FIND-CKD: Finerenone beyond diabetes | Hormone Insight Podcast

    Does finerenone slow kidney function loss in adults with chronic kidney disease without diabetes? In adults with albuminuric CKD without diabetes, finerenone slowed kidney function decline compared with placebo over 32 months, but hyperkalemia was more frequent. Randomized trial · NEJM 2026 Reference: Heerspink HJL, Neuen BL, Agarwal R, et al. N Engl J Med. 2026;395(6):533-545. doi:10.1056/NEJMoa2604625. PMID:42246672. Chapters 0:00 Intro 0:38 The trial 3:54 My take 4:38 Outro AI narration disclosure: This episode uses AI-generated narration. For healthcare professionals. Educational content only; not medical advice or a substitute for clinical judgement, individual assessment or current guidance. Hormone Insight: https://hormoneinsight.com/ Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856 Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

  7. 6d ago

    Prednisolone Once Daily vs Thrice-Daily Hydrocortisone in Adrenal Insufficiency: RCT Evidence

    Does once-daily low-dose prednisolone change short-term bone and metabolic outcomes compared with thrice-daily hydrocortisone in adults with established adrenal insufficiency? This four-minute Hormone Insight briefing examines a 9-month, double-blind, 2-period crossover randomised clinical trial. Forty-seven adults were randomised and 46 analysed; each regimen was given for 120 days with at least a 2-week washout. Primary findings with prednisolone were lower carboxylated osteocalcin by 1.22 ng/mL (95% CI -2.35 to -0.10; P=.04) and lower undercarboxylated osteocalcin by 1.38 ng/mL (95% CI -2.32 to -0.44; P=.005). Weight, waist circumference, BMI and HbA1c were also lower. Quality of life, lipids, blood pressure and overall adverse-event frequency did not differ significantly. Safety remains important: 133 adverse events occurred in 37 participants, including 3 serious events; 1 participant withdrew for hyponatraemia, there were 17 stress-related dose-doubling episodes, and no adrenal crises. These are short-term surrogate findings, not proof of fewer fractures, cardiovascular events or deaths. Limitations include the small single-centre sample, selected adults already established on replacement, 120-day treatment periods and unadjusted secondary P values. Educational content for doctors and health professionals; not individual treatment advice. Do not change glucocorticoid replacement without specialist review. Narration is AI-generated; no independent human clinical approval is claimed. Primary report: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2846925 PubMed: https://pubmed.ncbi.nlm.nih.gov/41874506/ Full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC13014172/ DOI: 10.1001/jamanetworkopen.2026.2982 | PMID: 41874506 Explore Hormone Insight: Website: https://hormoneinsight.com/ Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856 Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

  8. Sep 23

    VESALIUS-CV: Evolocumab Before a First Heart Attack or Stroke

    Hormone Insight examines whether evolocumab reduces first major cardiovascular events in a selected high-risk population without previous myocardial infarction or stroke. This is an appraisal of the primary VESALIUS-CV randomised trial, not a new study announcement. We cover the two primary composites, absolute benefit, adverse events, the statistical boundary around mortality findings, and clinical applicability. Key findings: • 12,257 participants; median follow-up 4.6 years. • Coronary heart disease death, myocardial infarction or ischaemic stroke: five-year Kaplan–Meier estimates 6.2% versus 8.0%; hazard ratio 0.75 (95% CI 0.65–0.86). • The 1.8 percentage-point difference corresponds to approximately 18 fewer people per 1,000 experiencing the composite over five years, derived from rounded risk estimates. • Adding ischaemia-driven arterial revascularisation: 13.4% versus 16.2%; hazard ratio 0.81 (95% CI 0.73–0.89). • Serious adverse events: 28.2% versus 28.9%; adverse-event treatment discontinuation: 3.3% versus 3.7%. Safety collection did not comprehensively capture minor adverse effects. Around two thirds already had qualifying atherosclerosis. These results should not be applied indiscriminately to generally healthy adults or everyone with diabetes. Mortality analyses below the failed coronary-death test in the hierarchy remain exploratory. Funded by Amgen; 93% of participants were White. No direct comparison against an active alternative such as ezetimibe. Primary source Bohula EA et al. Evolocumab in Patients without a Previous Myocardial Infarction or Stroke. New England Journal of Medicine. 2026;394:117–127. Online 8 November 2025; issue 8 January 2026. Article and supplement: https://www.nejm.org/doi/full/10.1056/NEJMoa2514428 PubMed: https://pubmed.ncbi.nlm.nih.gov/41211925/ Trial registration: https://clinicaltrials.gov/study/NCT03872401 AI-generated narration using an authorised voice. Medical education only, not individual medical advice or accredited CME.

    VESALIUS-CV: Evolocumab Before a First Heart Attack or Stroke
See All (25)

About

Discuss Diabetes and Endocrinology studies in a simplified manner. Expand your knowledge in Diabetes and Endocrinology.

Information

  • Creator
    FWA
  • Years Active
    2025 - 2026
  • Episodes
    25
  • Rating
    Clean
  • Copyright
    © Copyright 2024 FWA
  • Show Website
    Hormone Insight